title: Susceptibility to FAS-induced apoptosis in human nontumoral enterocytes: role of costimulatory factors.
abstract: FAS-FAS ligand interaction has been implicated in increased enterocyte apoptosis seen in immune-mediated bowel injury. However, scant information exists on the role of FAS in physiological enterocyte turnover. In the present study, the regulation of enterocyte FAS and FAS ligand expression by cytokines and its functional role in human intestinal epithelial cell apoptosis and proliferation were analyzed with two different models: a nontransformed human intestinal epithelial cell line (HIEC) and normal colonic explant cultures. HIEC constitutively expressed FAS, as analyzed by flow cytometry. However, stimulation with agonistic anti-FAS antibody (1-500 ng/ml) did not induce HIEC apoptosis. In contrast, in the presence of tumor necrosis factor alpha (TNFalpha) and/or interferon gamma (IFNgamma), HIEC became highly susceptible to FAS-induced apoptosis. The sensitizing effect to FAS-induced apoptosis was mediated via TNFalpha- and IFNgamma-induced upregulation of FAS expression (maximally 348%). Receptor studies showed that the effect of TNFalpha on FAS was mediated via the p55 TNF receptor. In colonic organ cultures, IFNgamma and TNFalpha also enhanced colonocyte FAS expression, resulting in a markedly increased apoptotic response to stimulation of this receptor, as shown by in situ terminal deosyuridine triphosphate nick-end staining. Neither FAS ligand expression nor its induction by cytokines was observed in HIEC or colonic explants. Proliferation studies showed that FAS is not implicated in regulating HIEC growth. These findings suggest that, despite the fact that normal human enterocytes express FAS, costimulatory factors, such as TNFalpha or IFNgamma, abundantly secreted under inflammatory conditions, are necessary to sensitize intestinal epithelial cells to FAS-induced apoptosis by upregulating this receptor.
authors.affiliation: Mucosal Immunology Laboratory, Division of Gastroenterology and Nutrition, Department of Pediatrics, Ste. Justine Hospital, University of Montreal, Montreal, Canada.
authors.forename: F M
authors.initials: FM
authors.lastname: Ruemmele
authors.forename: P
authors.initials: P
authors.lastname: Russo
authors.forename: J
authors.initials: J
authors.lastname: Beaulieu
authors.forename: S
authors.initials: S
authors.lastname: Dionne
authors.forename: E
authors.initials: E
authors.lastname: Levy
authors.forename: M J
authors.initials: MJ
authors.lastname: Lentze
authors.forename: E G
authors.initials: EG
authors.lastname: Seidman
mesh_terms: D015703:Antigens, CD / Q000187:drug effects; D017209:Apoptosis / Q000502:physiology*; D002455:Cell Division / Q000276:immunology; D002460:Cell Line; D004847:Epithelial Cells / Q000276:immunology / Q000473:pathology; D006801:Humans; D007421:Intestine, Small / Q000276:immunology* / Q000473:pathology; D008024:Ligands; D009924:Organ Culture Techniques; D018124:Receptors, Tumor Necrosis Factor / Q000187:drug effects; D047888:Receptors, Tumor Necrosis Factor, Type I; D013268:Stimulation, Chemical; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D015854:Up-Regulation; D019014:fas Receptor / Q000032:analysis* / Q000276:immunology
chemical_list: D015703:Antigens, CD; D008024:Ligands; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D014409:Tumor Necrosis Factor-alpha; D019014:fas Receptor